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Introduction: Leishmaniasis is a parasitic disease transmitted by phlebotomine
sandflies. Between 700,000 and 1.2 million cases of cutaneous leishmaniasis
and between 200,000 and 400,000 cases of visceral leishmaniasis (VL), which
is fatal if left untreated, occur annually worldwide. Liposomal amphotericin
B (LAMB), alone or in combination with other drugs, has been extensively
studied as VL treatment, but data on routine field use are limited, and several
challenges to patients’ access to this life-saving drug remain.
Areas covered: This article provides a review of clinical studies on LAMB for VL
and other forms of leishmaniasis. The current development of generic
versions of LAMB and related challenges are also discussed.
Expert opinion: LAMB proved to be highly efficacious and safe in over 8000 VL
patients treated by Me `decins Sans Frontie `res in South Asia, and its use was
feasible even at primary healthcare level. Despite requiring higher doses,
LAMB is the drug of choice to treat vulnerable groups (e.g., pregnant or HIV
positive) and relapsing VL patients in East Africa. LAMB should be included
in national VL guidelines and registered in all VL endemic countries. Its cost
should be further reduced and regulatory pathways to prove bioequivalence
for generic LAMB products should be implemented.
Keywords: drug access, generics, leishmaniasis, liposomal amphotericin B, review, treatment
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1. Background
Leishmaniasis is a parasitic and vector-borne disease transmitted by the phleboto-
mine sandfly. It occurs in several forms in humans, the two most common of which
are visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL). Among parasitic
diseases, leishmaniasis is responsible for the second-highest burden of disease after
malaria: 2,357,000 disability adjusted life years (DALYs). There are 350 million
people in 98 countries at risk of contracting the disease [1]; between 700,000 and
1.2 million cases of CL, and between 200,000 and 400,000 cases of VL occur annu-
ally worldwide. A lack of effective surveillance systems, however, makes it difficult
to ascertain the true burden of disease [2].
VL, also known as kala azar, occurs mainly in poor, remote areas in 70 countries
across South Asia, East Africa, Latin America and the Mediterranean region.
The five most affected countries are: India, Sudan, Bangladesh, South Sudan and
Ethiopia [2]. The disease is characterized by prolonged fever, enlarged spleen and
liver, substantial weight loss and progressive anemia. It is fatal if not treated. VL
is mainly caused by two species of the Leishmania parasite: L. donovani, prevalent
in South Asia and East Africa, and L. infantum, prevalent in the Mediterranean
region and in Latin America.
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.Cutaneous leishmaniasis has a wider geographical distribu-
tion. The five most affected countries are Afghanistan, Algeria,
Brazil, Iran and Syria [2]. The disease is characterized by lesions
on the skin, either self-healing or chronic. Some forms of CL,
particularly diffuse CL and mucosal leishmaniasis (ML) can
be severely disfiguring and extremely debilitating, causing
significant morbidity and, in some cases, death. There are
numerous causative species of CL, which differ in geographical
distribution, clinical presentation, the associated risk of
complications (e.g., ML) and response to treatment.
Finally, post-kala azar dermal leishmaniasis (PKDL), a
cutaneous complication of VL, can occur months or years
after initial successful treatment. PKDL is a potential parasitic
reservoir for VL, thus contributing to transmission of the
disease.
HIV co-infection, particularly with VL, is a growing
problem: co-infection often results in severe forms of the
disease, and is frequently refractory to treatment, even when
patients have started antiretroviral therapy.
This expert opinion publication will review the use of
liposomal amphotericin B (LAMB) for the treatment of leish-
maniasis, with a particular focus on VL, where its use has been
largely applied.
2. Medical need
Treatment objectives vary with the form of leishmaniasis. In
VL, the main objective of treatment is to save the patient’s
life, as the disease is fatal if untreated. Patients with severe
VL (e.g., severely anemic patients) are at increased risk of
death in the days following admission in the treatment center,
due to progression of the illness or drug-induced toxicity.
Drugs against VL therefore need to be rapidly effective and
safe. High drug efficacy is also essential to prevent relapses.
In South Asia and East Africa, where transmission of VL
remains anthroponotic (i.e., humans are the main reservoir
of the parasite), treatment can also play a pivotal part in dis-
ease control. In CL, the primary objective of treatment is to
reduce the duration and to heal the cutaneous lesion and,
for a limited number of species (e.g., L. braziliensis), prevent
the occurrence of mucous lesions.
2.1 Existing treatments
There are numerous drugs available for the treatment of VL
(and CL). A summary of these treatments is presented
in Table 1. Pentavalent antimonials -- sodium stibogluconate
(SSG) and meglumine antimoniate (MA) -- have been the
mainstay of treatment against VL for over five decades.
Drug resistance to antimonials, specifically in India, has
been a growing problem since the 1980s [3]. In addition, pen-
tavalent antimonials are associated with important toxicity
and, in the case of VL, with significantly high death rate, espe-
cially in some sub-groups of patients: severely ill, > 45 years,
HIV co-infected. For these reasons, development of new
drugs for leishmaniasis became a priority and several new
drugs have been introduced. Conventional amphotericin B
(deoxycholate) and later its lipid formulations, including lipo-
somal formulations (LAMB), were tested for use against VL
and introduced for this indication. This was followed by the
introduction of miltefosine (MF), the first oral treatment
against leishmaniasis, in 2002. Paromomycin (PM), a disused
aminoglycoside antibiotic, was also developed against VL and
was registered in 2006, initially in India.
Over the last 10 years, considerable efforts have been made
to develop either short courses (specifically for LAMB) or
combinations (co-administrations) of current drugs. A 17-day
regimen of SSG and PM has been shown to be as safe and
effective as the standard 30-day treatment of SSG in East
Africa [4]. This regimen was recommended in 2010 as a first-
line treatment for the region by a WHO expert committee [1].
Phase III trials were completed in 2010 for three double-
drug combinations (MF and PM, LAMB and MF, LAMB
and PM) and single-dose LAMB (10 mg/kg dose) in India,
all of which showed efficacy of above 95% [5,6].H o w e v e r ,
particularly for treatments in South Asia and East Africa, little
is known about the feasibility and field effectiveness of these
new treatments in a wide population.
Despite these developments, in the large majority of cases,
treatment of VL across the world still relies on pentavalent
antimonials or conventional amphotericin B, despite their
inherent toxicities or complex administration [7].M Fh a s
been increasingly used in India, Bangladesh and Nepal in
the last years, but there is recent evidence of its declining
efficacy in monotherapy [8]; and concerns remain about its
teratogenicity. Implementation of PM has been limited to
use in combination with SSG in East Africa, where its
uptake continues to increase. Use in monotherapy has
been avoided due to risk of resistance and its variable efficacy
between and within geographical regions [9].I t su s ei n
South Asia has been restricted to clinical studies. Large scale
use of LAMB will be discussed later, but has largely been
limited to a few key sites with the adequate resources to
use the drug.
3. Market review
Uncertainty on the disease’s true burden of VL in South Asia
and East Africa prevents a correct estimation of the current
and future market size. This uncertainty directly impacts on
drug demand forecasting, and subsequently on production
and pricing policies by pharmaceutical companies.
The demand for VL drugs is reliant on the treatment
recommendations adopted by high-burden countries. As
India alone accounts for 73% of global cases, the future
update of treatment guidelines in India will be critical to
determine the potential market for LAMB and other drugs
for VL.
With the vast majority of the 200,000 -- 400,000 VL cases
annually worldwide occurring in disadvantaged populations
in low- and middle-income countries, access to treatment
M. Balasegaram et al.
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.mostly relies on resources mobilized by donors, with the
market for VL drugs being widely shaped by donors’ policies.
Full financing of VL treatment programs by donors and
governments from endemic countries is important to increase
the attractiveness of the VL drug market to private companies.
4. Current research goals
Current research is now shifting away from developing
optimized regimens of existing drugs toward demonstrating
their implementation is feasible in the field. A joint project
by the Indian Council of Medical research (RMRIMS/
ICMR), the Indian National Vector Borne Disease Control
Programme (NVBDCP), the Bihar State Health Society
(BSHS), the Drugs for Neglected Diseases initiative
(DNDi), the WHO special program for tropical disease
research (TDR), OneWorld Health (OWH) and Me ´decins
Sans Frontie `res (MSF) is ongoing in India to implement a
pilot program and feasibility study on both combinations
and single-dose LAMB. In Bangladesh, TDR and ICDDR
have implemented a proof-of-concept feasibility study at
the primary healthcare level using a single 10 mg/kg dose of
LAMB. This will provide valuable information on wide-
scale use in the field, as well as facilitate access to LAMB-based
treatments.
The other major priority now is to develop new chemical
entities to treat leishmaniasis that will circumvent the key con-
straints of the current drugs, that is, toxicity, lack of feasibility
of use and/or high cost. DNDi, a product development part-
nership dedicated to the development of new treatments for a
number of diseases, including leishmaniasis, has developed a
target product profile (TPP) for drug research and develop-
ment for the treatment of VL (Table 2) [10,11]. Current drugs
are a far cry from even a minimal target profile developed
for a new chemical entity (NCE). Developing an NCE with
an optimal TPP is expected to allow greater feasibility of use
in the field, greater roll out and access to treatment and
sustainability of control and elimination efforts against VL.
Such a tool could also be used for CL, PKDL and for HIV
co-infected VL patients. Strategies for developing new medi-
cines for leishmaniasis include high-throughput screening
and sourcing of high quality leads to source NCEs, as well
as therapeutic switching and reformulating existing drugs
(e.g., oral formulations of amphotericin B). However, it
is unlikely that an NCE will be registered for use against
VL before 2018.
5. Review of LAMB use against leishmaniasis
This review will focus on the use of LAMB to treat
VL. Table 3 summarizes regimens involving LAMB for the
treatment of VL, some of which have only been developed
in the last 5 -- 6 years. Data on the use of LAMB for other
forms of leishmaniasis (CL, MCL and PKDL) are scarce
and summarized in the Box 1.
A review of the literature was undertaken on PubMed/
MEDLINE using the search terms ‘liposomal amphotericin
B’ and ‘visceral leishmaniasis’ (search performed on 10 July
2012). Selection criteria were used to include the following:
publications in English only, all clinical trials, observational
studies (including cohort studies and case series) including
over 10 patients. Of the 263 articles revealed in the original
search, 27 studies and clinical trials were included. These
studies are summarized in descending chronological order
in Table 4 [5,6,12-36]. The design and quality of the studies
varied, and included two Phase III, nine dosing/Phase II and
four other clinical trials, as well as eight retrospective and
four prospective observational studies. Of the 27 studies,
25 were performed using the AmBisome
  formulation, and
two using the Fungisome
  formulation (a generic LAMB
formulation manufactured by Lifecare in India).
Of note is that studies using non-liposomal lipid formula-
tions of amphotericin B are not included in Table 4. Compar-
ative studies report that different types of lipid amphotericin
B formulations have proved to be superior to conventional
amphotericin B formulation with higher drug concentrations
in the liver and spleen and lower concentrations in kidneys
and lungs, thus enhancing its efficacy and decreasing its
toxicity [37]. Nevertheless, LAMB has a better safety profile
compared with lipid formulations [1,38].
Over the last 20 years, studies have focused on several areas
of development. Initial studies (those published between
1994 and 1998) were early pivotal studies. Some of them
were used for a New Drug Application (NDA) to the United
States Food and Drug Administration (US FDA) [12,16]. This
led to the registration of AmBisome in 1997 for treatment of
VL, as well as for use as empirical therapy for presumed fungal
infections in febrile neutropenic patients, and treatment of
patients with systemic fungal infections refractory to conven-
tional amphotericin B [39]. A critical finding in these early
studies was that there appeared to be different dose require-
ments for LAMB in different endemic regions, with
South Asia (India) requiring lower doses than Europe (Medi-
terranean), Latin America (Brazil) or East Africa (Sudan,
Kenya) [40].
The next group of studies, those published between 1998
and 2005, focused on Phase II dose optimization studies,
mainly in the Mediterranean region of Europe and India.
The studies in Europe included separate groups of children
(the traditional patient population of L. infantum) and immu-
nocompromised/HIV+ adults. These observational studies con-
firmed earlier studies showing that total doses of 18 -- 20 mg/kg
appeared effective, at least in non-immunocompromised indi-
viduals [14,18,23,35]. However, longer-term outcomes of HIV
co-infected individuals appeared to be poor. Recent use in
high-dose monotherapy in HIV-positive VL patients in East
Africa has shown similar poor outcomes [24]. The second group
of studies, conducted mainly in South Asia, were driven by the
considerable interest in developing low-dose or single-dose
regimens of LAMB, given the profile of the drug formulation:
M. Balasegaram et al.
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.on the one hand safe and highly efficacious, and on the other,
relatively complex to administer and extremely expensive (the
WHO-negotiated price of AmBisome for treatment of VL
was as high as US$50 per vial at that time) [41]. These studies
confirmed the results of the early Phase II clinical trial by
Berman et al. and demonstrated high efficacy (over 90%)
with a dose as low as 5 mg/kg, as well as the feasibility and
safety of use in high single doses [29,30,36].
Since 2005, two interesting strategies have been investi-
gated, the first of which relied on developing combination
treatments using LAMB (specifically AmBisome) together
with other anti-leishmanial drugs. In India, trials were
supported by both TDR and DNDi. Phase II and III
trials demonstrated extremely high efficacy of low-dose,
short-course regimens involving only a single dose of
LAMB [5,33,34]. This led to the evaluation of LAMB combina-
tion regimens in both Africa and Latin America, where trials
are still ongoing (in co-administration with MF and MA,
respectively) [42,43].
The second strategy looked into the use of single-dose
LAMB, specifically for the South Asia focus. A pivotal
Phase III trial published in 2010 by Sundar et al. demonstrated
high efficacy (> 95%) and safety of a single 10 mg/kg dose of
LAMB [6]. This prompted the WHO expert committee on
the control of leishmaniasis to recommend the regimen as
first-line treatment for VL in South Asia that same year [1].
Table 2. TPP for new clinical entities against VL (as monotherapy)*.
Optimal target profile Minimal target profile
Target label VL and PKDL VL
Species All species Leishmania donovani
Distribution All areas Either India or Africa
Target population Immunocompetent and immunosuppressed Immunocompetent
Clinical efficacy > 95% > 90%
Resistance Active against resistant strains
Safety and tolerability No AEs requiring clinical monitoring One clinical monitoring visit in mid/end point
Contraindications None Pregnancy/lactation
Interactions None -- compatible for combination therapy None for malaria, TB and HIV concomitant therapies
Formulation Oral/i.m. depot Oral/i.m. depot
Treatment regimen 1/day for 10 days p.o./3 shots over 10 daysz b.i.d. for < 10 days p.o.; or > 3 shots over 10 days
Stability 3 years in zone 4 Stable under conditions that can be reasonably
achieved in the target region (> 2 years)
Cost < US$10/course < US$125/course
*Developed by and reproduced with permission by DNDi.
zFor primary VL only. PKDL, HIV co-infection and relapse case treatments may require longer treatment durations.
DNDi: Drugs for Neglected Diseases initiative; PKDL: Post-kala azar dermal leishmaniasis; TPP: Target product profile; VL: Visceral leishmaniasis.
Table 3. Potential regimens of LAMB that have been developed for use against VL*.
Regimen Cost (USD) [70] Efficacy (phase of
trial done)
Comments
LAMB i.v. 10 mg/kg single dose 126 95% (P3) South Asia only, poor efficacy in
East Africa
LAMB 20 mg/kg over 4 doses 252 98% (P4) South Asia only and possibly
Europe and Latin America, poor
efficacy in East Africa
LAMB 5 mg/kg + MF 100 mg/kg/day for 8 days 88 -- 109 97.5% (P3) South Asia only; teratogenicity
of MF may hinder uptake
LAMB 5 mg/kg + PM 15 mg/kg/day for 11 days 79 97.5% (P3) South Asia only; use of daily PM
injections may hinder uptake
LAMB 30 mg/kg over 6 -- 10 doses 378 90% (observational
field data only)
East Africa only; no clinical trial
data available at this dose
*Based on data from the WHO expert committee report 2010.
LAMB: Liposomal amphotericin B (all trials here have used AmBisome
 ); MF: Miltefosine; PM: Paromomycin.
Liposomal amphotericin B as a treatment for human leishmaniasis
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.Of additional interest, a trial in East Africa (Sudan and
Ethiopia) involving single doses of LAMB (AmBisome) has
recently been terminated [44]. Results are due to be published
soon; however, other recent data confirmed early findings
that high doses of LAMB were required to achieve definitive
cure (6 months) rates of even 90% [22,26].
It is difficult to predict if use of LAMB in single dose may
increase the risk of drug resistance, as has occurred with SSG
in India (where short course treatments of the drug were
used). The mode of action of amphotericin B on membrane
ergosterol is such that an organism would have to undergo
significant changes in order to become resistant. Moreover,
it is likely that the LAMB single-dose regimen will improve
compliance and therefore reduce the risk of underdosing.
There is evidence that resistance may not be easily generated
in practice as was shown in a small study of 10 HIV-VL
co-infected patients who were exposed to long-term treatment
of LAMB, with no changes in drug susceptibility of the
patient parasite isolates [45]. By contrast, an earlier study has
demonstrated a reduction in amphotericin B susceptibility
(IC90 and IC50) in promastigote and intracellular amastigote
forms of Leishmania sp. in immunocompromised patients
treated with a lipidic emulsion of amphotericin B [46].I n
addition, the recent exploration and in vitro elaboration of
mechanisms of L. donovani resistance to amphotericin B
suggest that there are indeed pathways to resistance [47].
6. Competitive environment
AmBisome, the liposomal formulation of amphotericin B
produced by Gilead, is one of the very few liposomal formu-
lations to have been registered by the US FDA and other
stringent national drug authorities since the potential of
liposomes as a drug delivery system was discovered in the
1970s (Table 5).
A liposome is a microvesicle composed of a bilayer of lipid
amphipathic molecules enclosing an aqueous compartment
that can entrap hydrophilic, as well as lipophilic drugs. The
liposome acts as a masking system for the encapsulated
drug: as long as the liposome is intact, the drug is isolated
from the environment and protected from metabolism and
inactivation in the plasma. The versatility of a liposome’s
design (composition, morphology, size and surface characte-
ristics) enables more targeted distribution and consequent
improvement in the therapeutic index.
Despite research and development and investment in lipo-
somal formulations, guidance on the regulatory pathways for
the registration of generic versions of liposomal formulations
is still lacking, even in stringent regulatory authorities where
the expiry of patents and data exclusivity should open up
the market to generic competition for AmBisome and other
medicines with liposomal drug delivery systems (e.g., pegy-
lated liposomal doxorubicin). As a result, in 2012 MSF began
Box 1. Review of LAMB treatment for cutaneous, mucosal and post-kala azar leishmaniasis as leishmaniasis
also refer back to cutaneous and mucosal.
CL
Geographical distribution of CL, its clinical features, potential to spread (e.g., to mucosae), as well as recommended treatment
(e.g., local vs systemic) and response to anti-leishmanial drugs vary with the Leishmania species [71]. Published data on LAMB
use for CL are limited to individual case reports or small case series. Out of 19 patients with CL caused by various Leishmania
species, treatment with LAMB (median total dose: 21 mg/kg) was curative in 16 (84%), while 3 patients required a second
course of LAMB [72]. In Israel, 11/13 (83%) patients with L. tropica and 29/34 (85%) travelers with L. braziliensis CL (88%
returning from Bolivia) were cured with LAMB (total dose: 18 mg/kg) [73,74]. In the L. braziliensis CL study, LAMB was more
effective and better tolerated than SSG administered for 3 weeks. However, in Brazil, only 50% of 16 patients with CL caused
by various Leishmania species who received a lower dose of LAMB (total dose: 7.5 mg/kg) were cured [75]
ML
In contrast to CL, patients with ML do not self-heal and require systemic treatment. Pentavalent antimonials and conventional
amphotericin B have been the mainstay of ML treatment during the last decades with 51 -- 88% reported cure rates [76]. There
are very scarce published data on LAMB use for ML. In Brazil, 5/6 (83%) patients unresponsive to antimonials were cured after
receiving 2 -- 3 mg/kg/day for a minimum of 20 days [77]. The largest case series includes eight patients who were cured after a
mean total dose of 35 mg/kg of LAMB [78], which is lower than the total dose recommended in the most recent WHO
technical report (40 -- 60 mg/kg)
PKDL
Anti-leishmanial therapy is indicated in severe or prolonged PKDL in East Africa and in all forms of PKDL in South Asia.
Treatment still relies on prolonged -- sometimes up to several months -- regimens of pentavalent antimonials, which are
cumbersome, painful (daily intramuscular injections) and sometimes toxic. LAMB (2.5 mg/kg/day for 20 days) was successful in
10/12 (83%) patients with SSG-unresponsive PKDL in Sudanese patients [79]. Apart from rare isolated case reports, there are no
other published case series of LAMB use in PKDL. In Bangladesh, a large cohort (n = 1303) of PKDL patients were recently
treated with LAMB (5 mg/kg twice a week for 3 weeks; 30 mg/kg total dose) with encouraging results (K. Ritmeijer, personal
communication)
CL: Cutaneous leishmaniasis; LAMB: Liposomal amphotericin B; ML: Mucosal leishmaniasis; PKDL: Post-kala azar dermal leishmaniasis;
SSG: Sodium stibogluconate.
M. Balasegaram et al.
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.to collect data on generic versions of LAMB and on the
regulatory challenges associated with their evaluation.
In 2002, the US FDA published draft guidance on lipo-
somal drug products intended for the industry [48].T h i si s
currently under review. In 2010, the FDA also published
product-specific draft guidance for determining the bio-
equivalence of doxorubicin pegylated liposomal injectable
formulations [49]. The European Medicines Agency (EMA)
published a ‘draft reflection paper’ in 2011 to assist appli-
cants in the generation of relevant data (quality, clinical
and non-clinical) to support a marketing authorization for
intravenous liposomal products developed with reference to
an innovator liposomal product [50]. All these drafts contain
non-binding recommendations. No other National Drug
Regulatory Authority (NDRA) belonging to the Interna-
tional Conference on Harmonisation, and therefore consid-
ered stringent, has published standards for evaluating
generic liposomal formulations and/or assessing bioequiva-
lence. Moreover, no NDRA from VL-endemic countries or
from countries manufacturing generic versions have such
standards. A few NDRAs refer to the US FDA and EMA
draft guidance. In this vacuum, WHO has not set any stand-
ards for liposomal formulations to support countries in the
evaluation of liposomal products. The debate on how to
prove bioequivalence and allow the registration of generic
versions has been brought into the public domain. Contri-
butions to the debate have come from NDRAs, academic
experts and also from studies funded by innovator pharma-
ceutical companies [51-57]. According to a group of academic
experts, the classical bioequivalence approach could be
applicable, if properly adapted [57].
The uncertainty of the regulatory pathway is one of the
elements impeding the entry of generic competitors to strin-
gently regulated markets [53]. This vacuum in guidance also
has an impact on access to generic versions of LAMB pro-
duced and marketed in other countries. Through the survey,
the authors found that a number of generic LAMB formula-
tions have already been marketed in a few countries or are
under development as reported in Table 6. The lack of
guidance and the absence of an internationally recognized
system for evaluation of generic products, such as the WHO
prequalification system set for vaccines, HIV, TB and Malaria
medicines, are major obstacles impairing the search for alter-
native quality-assured options to the innovator product.
Currently, the main incentive behind the development of
generic LAMB is to compete with AmBisome for more lucra-
tive conditions and markets than VL, as most of the US
$330 million annual revenue that comes from AmBisome
relates to sales in high-income countries. The innovator com-
pany Gilead now offers AmBisome at the WHO-negotiated
price of US$18 per vial for VL in developing countries
(‘access price’). Outside developing countries, and for condi-
tions other than VL in developing countries, the ‘commercial
price’ is about 10 times higher: the price of AmBisome in the
UK and South Africa is US$150 and US$230 per vial,
respectively [58,59].
The generic manufacturers contacted during the MSF
survey appeared open to discuss prices and volumes for
VL treatment with stakeholders like WHO and MSF.
A number of manufacturers were developing their products
with a view to entering the US and European markets.
However, if the market size of LAMB for VL
expanded -- for example, through large-scale public procure-
ment mechanisms -- those competitors could also enter the
less profitable, but still attractive, VL market. The increased
competition would drive the price of LAMB down and would
be beneficial for patients with VL as well as patients who need
LAMB for other conditions [41].
Finding alternative sources of LAMB is even more essential
given that a single plant is currently responsible for the world-
wide production of AmBisome. As declared by Gilead: ‘in the
event of a disaster, including an earthquake, equipment failure
or other difficulty, we may be unable to replace this
manufacturing capacity in a timely manner and may be
unable to manufacture AmBisome to meet market needs’ [60].
Finally, the inferior profile of existing generic LAMB for-
mulations in terms of thermostability should not deter the
search for and investigation of alternative sources of LAMB.
A cold chain with a narrow temperature range (2 -- 8 C)
was also required for AmBisome when it was first registered
and marketed; further stability data later led to an extension
of the upper storage temperature range to 25 C [61].I ti s
not excluded that generics under development may reach a
thermostability profile similar to that of AmBisome.
Table 5. Injectable liposomal products approved by the US FDA.
Trade name Drug formulation Year of US FDA approval
Doxil
  Pegylated liposomal doxorubicin injection 1995
Daunoxome
  Liposomal daunorubicin injection 1996
Ambisome
  LAMB injection 1997
Depocyt
  Liposomal cytarabine injection 1999
Visudyne
  Liposomal verteporfin injection 2000
Definity
  Liposomal perflutren injection 2001
Depodur
  Liposomal morphine sulfate injection 2004
Exparel
  Liposomal bupivacaine injection 2011
LAMB: Liposomal amphotericin B; US FDA: United States Food and Drug Administration.
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.7. Conclusion
LAMB is a very safe and highly effective treatment for pri-
mary VL in L. infantum endemic areas and in the L. donovani
South Asian focus (India, Bangladesh, Nepal), where it was
recently recommended as first-line treatment by the WHO
expert committee on the control of leishmaniasis [1]. In East
Africa, the optimal total dose of LAMB to cure primary VL
remains to be determined, but will be higher than in other
endemic areas. Therefore, LAMB cannot be recommended
as first-line treatment for VL in this region, except for patients
at increased risk of death with pentavalent antimonials-based
treatments. Additional research is needed to better define
the indication of LAMB for other forms of leishmaniasis
(CL, MCL, PKDL) and to design optimal (combination)
regimens for HIV co-infected patients.
Several generic LAMB formulations already exist and many
others are under development. Their introduction in the mar-
ket is however happening without clear standards to which
companies can refer to and abide by. Stringent regulatory
authorities have not been issuing definitive guidance on the
evaluation of generic liposomal formulations.
The recommendation to use LAMB as first-line treatment
for VL in most regions needs to be coupled with a sustainable
plan for its use in endemic countries. In the short term, fur-
ther reductions of the ‘access price’ should be negotiated
with Gilead, while in the longer term the pool of suppliers
to national VL control programs should be expanded. Large
public procurement schemes for LAMB as a VL treatment
could also represent an attractive market to manufacturers
who currently target only niche markets for the treatment of
fungal infections for countries or patients who can afford to
pay. Major stakeholders in control of leishmaniases, such as
WHO and donors, should jointly invest in ambitious plans
to support access to generic affordable quality-assured
formulations of LAMB for VL.
8. Expert opinion
In this section, the authors will describe the practical experi-
ence acquired by MSF teams and partners on the use of
AmBisome for treating VL in rural areas of South Asia and
East Africa. They will then discuss the remaining barriers
preventing a large-scale use of LAMB for VL and suggest
some ways to remove them.
8.1 MSF experience in India and Bangladesh
In mid-2007, MSF began reinforcing existing VL diagnostic
and treatment services in the highly endemic Bihar district
of Vaishali in India, with support from the State Health
Society, the Rajendra Memorial Research Institute (RMRI)
and the National Vector Borne Disease Control Programme.
LAMB 20 mg/kg (4 doses of 5 mg/kg over 5 -- 10 days,
depending on clinical condition) was introduced as first-
line treatment, both at district hospital and Primary Health
Care (PHC) levels (Figure 1). It was felt critical to demonstrate
feasibility of LAMB use at the PHC level, where the majority
of patients in rural India currently access healthcare.
Up until June 2012, 6766 patients were treated at the
district level inpatient facility, while 1440 were treated at
the PHC level, and only 4% were treated at a tertiary referral
center. Of all the patients diagnosed at the PHC level, just
over a quarter (26.3%) required referral to inpatient
facilities for VL treatment. Initial clinical cure (i.e., improved
Table 6. Overview of LAMB formulations introduced in the market or under development*.
Company Country Brand name Year of marketing
approval in the
country of origin
Storage conditions Presentation (special warnings
before use)
Gilead USA AmBisome
  1997 Below 25 C Lyophilized (reconstitution, filtration
and dilution before use)
Lifecare India Fungisome
  2003 2 -- 8 C Liquid (sonication 45 min before use)
Cipla India Phosome
  2008 2 -- 8 C Lyophilized (reconstitution, filtration
and dilution before use)
Sun Pharma India Lambin
  2009 2 -- 8 C Lyophilized (reconstitution, filtration
and dilution before use)
Lyka Labs India Lipholyn
  2010 2 -- 8 C Lyophilized (reconstitution, filtration
and dilution before use)
Celon Labs India Under development 2 -- 8 C Lyophilized (reconstitution, filtration
and dilution before use)
Laboratorios
Richmond
Argentina Withdrawn, under further development (Anfogen) Lyophilized (reconstitution, filtration
and dilution before use)
Genex Pharma India Under development
Claris Lifescience India Under development
TTY Pharma Taiwan Under development
*This table is not exhaustive as some producers from India and Taiwan have chosen not to disclose information about their products under development.
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.symptoms, cessation of fever and recession of spleen following
the last dose of LAMB) was achieved in 98.1% of patients,
1.4% defaulted before or during treatment and 0.4% patients
died before, during or immediately after treatment (Figure 2).
In addition, LAMB was found to have a very low rate of
adverse reactions: approximately 8% of patients reported
adverse events -- mainly minor -- during treatment, with
five patients with hypersensitivity requiring cessation of
LAMB and switching to an alternative treatment. Only
1.2% of immunocompetent patients were readmitted with
VL relapse after an average post-treatment period of
12.4 (7.4) months. The rate of relapse was higher (13.7%)
in the 167 HIV co-infected patients.
Although typically considered feasible at the hospital level,
the major challenge at the PHC level was to maintain a reli-
able cool chain to store AmBisome between 2 and 8 C until
2011, as was required by the Indian drug authorities, and
below 25 C since then. After starting with a complex and
logistically heavy passive cold chain requiring regular changes
of ice packs, a simpler solution was found when the state
authorities provided dedicated Ice Lined Refrigerators (ILRs)
for use to store AmBisome at both PHC and hospital levels.
Since the start of the program, over 17,000 vials have been
successfully used in PHCs. Since the change of temperature
requirements (up to 25 C), it is now possible to store AmBi-
some in air-conditioned rooms, ensuring a back-up generator
can guarantee no power cuts.
The second major constraint was the perception that such a
‘complex’ treatment could not be safely and effectively admin-
istered at the PHC level for lack of skilled human resources.
After being trained, health workers in PHC centers proved
to be able to independently prepare and administer the appro-
priate dose of LAMB on an ambulatory basis, and identify
patients with more severe disease for referral to the district
level inpatient treatment facility. Finally, another major issue
faced was the complexity of importing AmBisome into India,
where it is registered but not produced.
In Bangladesh, since May 2010, MSF provides VL treat-
ment services in PHC settings in the VL hyper-endemic
sub-district of Fulbaria, in the Mymensingh district, using
an ambulatory treatment regimen of 15 mg/kg LAMB (three
doses of 5 mg/kg on day 0, 1 and 5). As of July 2012,
1439 immunocompetent primary VL patients had been
treated, with an initial cure rate of 99.6%, 4 deaths (0.3%)
and 1 (0.1%) defaulter. Active follow-up of patients at 1,
6 and 12 months post-treatment showed that 39 patients
(2.7%) had relapsed, the majority of which (90%) after
6 months post-treatment. These data confirm that very
favorable outcomes can be achieved in PHC settings with a
15 mg/kg dose of LAMB.
In summary, LAMB 15 -- 20 mg/kg total dose has shown
very high cure rates and a very low rate of adverse reactions
and relapses under field conditions in India and Bangladesh.
Although the use of LAMB in hospital settings is more widely
recognized, with appropriate training and commitment, its
use is feasible, safe and effective at the PHC level, utilizing
logistic and human resources that already exist within the
public health system. The ongoing proof-of-concept studies
in India and Bangladesh will show whether similar outcomes
can be achieved even with a single 10 mg/kg dose.
8.2 MSF experience in East Africa
In East Africa, where pentavalent antimonials still remain the
mainstay of VL treatment, LAMB was introduced in MSF
programs in the 1990s for the treatment of severe and compli-
cated VL [26]. Patients with severe or complicated VL have a
poor tolerability for antimonials, resulting in a significantly
increased mortality risk [62]. Because of its more favorable
Figure 1. Young female patient with visceral leishmaniasis
receiving liposomal amphotericin B infusion at Vaishali
District Hospital, Bihar State, India.
Day 1  Day 2  Day 3  Day 4  Day 5 
Figure 2. Nursing chart showing rapid clearance of fever
after initiation of liposomal amphotericin B treatment in a
patient with visceral leishmaniasis at Vaishali District
Hospital, Bihar State, India.
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.safety profile, LAMB is the first-line treatment in pregnancy,
due to the high risk of spontaneous abortion with anti-
monials [21], as well as in elderly VL patients, because of
high antimonial toxicity-related mortality in patients over
45 years of age [63]. Because of the poor tolerability and high
mortality associated with pentavalent antimonials in HIV
co-infected VL patients, LAMB is the recommended drug
of choice in this patient group, even though its efficacy is
limited [24].
The total dose of LAMB needed to establish cure in East
Africa was found to be much higher than that required in
South Asia. Initially, a regimen was used with a total dose of
20 mg/kg LAMB, divided over 6 doses on alternate day
(Figure 2). However, over the years, there has been growing
evidence of significant treatment failure rates with this
dose [22], especially in patients with complicated VL and
concomitant infections, such as TB and HIV. Therefore, the
recommended total dose of LAMB in East Africa for
non-HIV-infected VL has been increased to 30 mg/kg.
The use of AmBisome in East Africa was initially limited,
for several reasons: its prohibitively high price, its intravenous
administration, the lack of trained health staff and the tem-
perature requirements to transport and store it. It meant
that LAMB could only be used in referral hospital settings.
Successive negotiations resulting in a decrease of the ‘access
price’ and the gradual expansion of cold chain capacity and
trained health staff to peripheral health centers in remote
and extremely resource-poor endemic areas in East Africa
have increased access to LAMB for patients from specific
vulnerable groups with poor tolerability for pentavalent
antimonials. This has contributed to the gradual decrease in
overall VL mortality in MSF programs, from above 10% in
the 1990s to well under 5% in recent years [64,65].
8.3 Access to LAMB: bottlenecks that prevent
large-scale implementation
VL, like other neglected tropical diseases, predominantly
affects poor populations. In South Asia, it is linked to poor
housing and unhealthy living environments [66]. Economic
and social exclusion are strong underlying determinants
of poor access to VL treatment, as a recent study of low-
caste Indians with the disease indicates [67]. Access to timely
diagnosis and prompt, effective treatment is hindered by geo-
graphical, financial and social obstacles. Lack of knowledge
about the disease and treatment options among both patients
and physicians results in delays in seeking treatment. For peo-
ple in East Africa, physical distance from health facilities is a
major problem. The private market, traditional healers and
quacks can also pose barriers to quality care.
8.3.1 Storage and drug administration
There are also very specific drawbacks preventing access to
LAMB for VL. The temperature requirement for the trans-
port and storage of AmBisome, which is now up to 25 C, is
a significant challenge in the countries where the disease
is most endemic, such as India and Sudan, where tempera-
tures can exceed 45 C. Adding a cold chain monitor to vials
(similar to those used with vaccines) would help guarantee
that the drug can be used safely. In addition, LAMB is admi-
nistered intravenously, and therefore requires trained staff.
These obstacles to the uptake of this treatment can be over-
come but only with adequate resources, as shown by MSF’s
experience in East Africa and South Asia.
8.3.2 Implementation of guidelines
While the recommendations of the WHO expert committee
on leishmaniasis have been implemented in most endemic
East African countries (SSG and PM as first-line treatment),
they have not yet been properly translated in South Asian
countries. The WHO committee considered LAMB single
dose (10 mg/kg) or LAMB short course (15 mg/kg) as the pre-
ferred option for first-line VL treatment in the Indian subcon-
tinent, and combination therapies (LAMB and MF, LAMB
and PM, MF and PM) as other possible first-line options [1].
In Bihar, the Indian state with the highest VL burden, MF
monotherapy is recommended by the national program as
the first-line treatment. Also in Bangladesh, MF monotherapy
is still recommended by the Ministry of Health as first-
line therapy. Integrating the latest evidence-based treatment
recommendations into national guidelines is a first step
toward facilitating access to LAMB. Adherence to the WHO
recommendations is likely to improve when the above-
mentioned field feasibility studies concerning LAMB in
monotherapy or in combination are available.
8.3.3 Need for registration
For a drug to be easily imported into a country, it needs to be
registered by the national drug authority. The AmBisome
Access label product is now registered in most developing
countries with a high VL burden (Bangladesh, Ethiopia,
Kenya and Sudan), but not yet in India. Although it has not
been registered in India, MSF has been able to treat patients
in the country with AmBisome for the last 5 years, initially
through an agreement with the RMRI, and more recently
through its own import license. All high-burden countries
should include LAMB in their national treatment guidelines
and in their Essential Medicines List, while Gilead should
be encouraged to deploy more efforts to register access label
AmBisome in all VL-endemic countries.
8.3.4 Bringing down prices
The WHO-negotiated prices of AmBisome (US$20 per vial
in 2006, then US$18 per vial in 2008) have increased access
to LAMB in developing countries, notably in MSF projects,
where it is now routinely used. This ‘access price’ is, however,
still too high for many health systems in developing countries:
a full course of treatment for an average VL patient (weight:
35 kg) is estimated to cost between US$126 and US$378,
depending on the necessary dosage. A study published in
2010 compared the cost-effectiveness ratios of 10 treatment
M. Balasegaram et al.
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.strategies in the Indian subcontinent. The MF and PM com-
bination was found to have the best cost-effectiveness ratio [68].
According to the authors, ‘if the price of a LAMB vial is
decreased (…) to less than US$ 9.8, then [single-dose
LAMB -10 mg/kg] becomes the most cost-effective strategy’.
Based on these findings, MSF has been asking Gilead to
reduce the price of AmBisome to US$10 per vial.
In December 2011, Gilead agreed to donate 445,000 vials
of AmBisome, under the supervision of the WHO, for the
treatment of more than 50,000 VL patients over the next
5 years. The scope of this donation is very limited. Fewer
than 5% of patients with VL will benefit from the donation,
and India, the country with the highest VL burden, is not a
recipient [69]. This donation also reduces the size of the market
for VL treatment, and thereby helps discourage other compa-
nies from targeting the market with alternative or generic
LAMB formulations. Extending the donation would only be
a solution if it sustainably covered the needs of all VL patients
in developing countries who need LAMB.
The market for LAMB is now dual and segmented: there is
a WHO-negotiated ‘access price’ for VL in developing
countries, and a much higher and lucrative price in wealthy
markets. Gilead’s tiered pricing policy, which was not pushed
by a strong competitive environment, but rather by negotia-
tions with WHO, has not achieved the price levels that are
necessary for full uptake in developing countries [41]. Compe-
tition with generic producers, if promoted by an enabling
environment, would be likely to bring prices down further,
but making generic LAMB formulations available at a lower
price than the current AmBisome ‘access price’ is unlikely to
be feasible without a clearer and stronger demand. Generics
producers are more interested in lucrative potential sales for
the other indications of LAMB than in occasional small-
scale public procurement for national leishmaniasis programs.
Securing high-volume public calls for tender will be critical to
the creation of a more predictable and larger market for
LAMB for VL. Finally, bringing down prices through
enhanced competition with generics suppliers would also
help to facilitate access to LAMB in developing countries for
other conditions, notably cryptococcal meningitis.
8.3.5 Implementation of regulatory pathways to
prove bioequivalence for generic liposomal products
As discussed previously, even stringent regulatory authorities
have not been able to provide guidance to manufacturers
wishing to enter the market in high-income countries. The
lucrative markets for LAMB will be open to Gilead’s compet-
itors within the next 2 -- 5 years. AmBisome is protected by
two patents (US 5874104 and US 5965156) in the USA until
2016 and by one patent (CA 1339008) in Canada until 2014.
The de facto monopolistic situation of Gilead on the LAMB
market is likely to continue beyond these dates. Indeed, scien-
tific, regulatory and manufacturing hurdles have now been
recognized as clear opportunities for extending market exclu-
sivity beyond patent protection for therapeutic nanoparticles
like LAMB [53].
Price is a key barrier to access to LAMB in endemic
countries, but it is certainly not the only issue. Attention
needs to be paid to the quality of generic versions, in order
to ensure that patients benefit from the efficacy and low tox-
icity of LAMB, as opposed to conventional amphotericin B
and other lipidic formulations. Both demand and supply of
LAMB need to be improved. This requires a plan to expand
the pool of LAMB suppliers, which involves the WHO,
governments of endemic countries and donors. Within the
London Declaration, a global coalition for neglected tropical
diseases, new stakeholders, including the UK Department
for International Development, have pledged more support
to VL-control programs. Better access to quality-assured
affordable LAMB for VL treatment should be a priority
objective within this new initiative.
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